Loading...
Tardive dyskinesia (TD) is an involuntary movement disorder that can occur with prolonged exposure to typical or atypical antipsychotics. Because these are increasingly used for nonpsychotic disorders, rates of TD have been rising. People with nonpsychotic disorders and TD may experience distress from even slightly noticeable abnormal movements, and mood disorders are an independent risk factor for TD. In 2017, valbenazine was approved by the FDA for TD in adults. However, little is known about the medication's effectiveness and safety in individuals with mood disorders only. To learn more, investigators retrospectively pooled data from two 6-week, placebo-controlled trials of valbenazine for antipsychotic-induced TD (e.g., NEJM JW Psychiat…